Long-Term Follow Up of VOY-101 Non-nAMD Extension Study

NCT07660640 · tracked via the Priya Life Science USA tracker

Sponsor

Perceive Biotherapeutics, Inc.

Phase

Observational

Started

2026-03-03

Last updated

2026-06-22

Condition(s) studied

Age-Related Macular Degeneration (AMD)Non-Neovascular Age-Related Macular Degeneration

Investigational drug(s) / intervention(s)

observational studyVOY-101

observational study: No intervention - observational study

VOY-101: One-time intravitreal injection of VOY-101.

Study summary

Long-Term Follow Up Extension for participants previously enrolled in a VOY-101 study for Advanced Non-Neovascular Age-Related Macular Degeneration

Eligibility

Sex

ALL

Min age

50 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Have received an injection of VOY-101 and exited either the PBI-AMD-001 or PBI-AMD-002 Phase 1/2a study of VOY-101. 2. Are willing and able to understand and provide informed consent. Exclusion Criteria: There are no exclusion criteria for this study

Primary outcome measure(s)

Frequency of ocular and systemic VOY-101 related AEs — 3 years
Frequency of ocular and systemic VOY-101 related AEs (serious \[SAEs\] and treatment-emergent non-serious adverse events \[TEAEs\]).

Trial sites (4)

Facility	City	Region
Ophthalmic Consultants of Boston	Boston	Massachusetts
Retina Consultants of Texas	Bellaire	Texas
University of Utah	Salt Lake City	Utah
Sourasky Medical Center - Ichilov	Tel Aviv	Israel

More Perceive Biotherapeutics, Inc. trials in the USA

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration Active, not recruiting

Other trials for the same condition

Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration Recruiting

Study Evaluating the Efficacy and Safety of Chloroprocaine HCl Ophthalmic Gel 3% vs Proparacaine Ophthalmic Solution 0.5% Plus Subconjunctival Lidocaine in Patients Undergoing Intravitreal Injections Enrolling by invitation

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration Active, not recruiting

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07660640 on ClinicalTrials.gov ↗ ← All trials in the USA